This project builds on Telethon Kids Institute’s previous work testing a novel anti-cancer immunotherapy, anti-CD47.
Brain cancer kills more Australian children than any other disease. Tragically, up to 80 percent of patients with high-grade-gliomas (HGG) will die within five years.
Pre-clinical studies have found anti-CD47 awakens the brain’s immune system to attack cancer.
Read more: Pre-clinical anti CD-47 therapy
This continued funding will allow the team to investigate whether combining anti-CD47 with standard radiotherapy in HGG can further increase survival. The project, led by Professor Nick Gottardo, will determine whether to progress this combination therapy to clinical trials for children with HGG.
Additional funding has been provided by The Pirate Ship Foundation, The Stan Perron Foundation, Channel 7 Telethon Trust and The Cancer Council of NSW.